ALX Oncology to Present at 2026 Jefferies Global Healthcare Conference, Highlighting Oncology Pipeline
Decision brief
Answer first · skim in under a minute
ALX Oncology is set to present its oncology pipeline at the 2026 Jefferies Global Healthcare Conference in New York. The presentation, scheduled for June 3rd, will feature a fireside chat format and will be webcast live.
ALX Oncology said it will join a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on June 3. The oncology-focused session is a chance for investors to hear management frame evorpacept and ALX2004, not a new pivotal readout.
Contents9 sections
Key Takeaways
- ALX announced a Jefferies fireside chat for June 3, 2026, at 5:30 PM ET in New York.
- A webcast will be archived for up to 90 days on the company investor site, per the June 1, 2026 release.
- Lead asset evorpacept is in multiple cancer trials; ALX2004 is in Phase 1 for EGFR-expressing solid tumors.
- ASPEN-06 (NCT05002127) is one registered evorpacept study in advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
What did ALX announce for Jefferies?
In a GlobeNewswire release dated June 1, 2026, ALX Oncology Holdings Inc. (Nasdaq: ALXO) said leadership will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York. Format is a fireside chat. Date is June 3, 2026. Time is 5:30 PM ET.
The company said investors can access the webcast through the Events section of its investor site and that the replay will be archived for up to 90 days after the presentation date.
Why does this oncology conference slot matter?
Jefferies’ New York healthcare conference concentrates public biotech and pharma meetings into a short window. For a clinical-stage oncology name, the fireside chat is mainly a capital-markets and narrative update. Listeners should separate management tone from new clinical tables. If slides recycle prior data cuts, treat them as reminders, not as fresh primary endpoints.
Conference calendars also cluster competing oncology stories. An ALXO slot on June 3 sits beside hundreds of other public-company meetings across June 3–4. That density can mute a fireside chat unless management teases a near-term data cut, partnership, or financing plan. Ask whether the webcast adds numbers that were not in the last 10-Q or press release.
What pipeline context should listeners bring?
ALX positions evorpacept as a lead immuno-oncology candidate across multiple ongoing cancer trials. It positions ALX2004 as a novel EGFR-targeted antibody-drug conjugate with an ongoing Phase 1 dose-escalation trial in patients with EGFR-expressing solid tumors. Those descriptions come from the same conference announcement.
One registered study is NCT05002127 (ASPEN-06), a Phase 2/3 evaluation of evorpacept in advanced HER2-overexpressing gastric or gastroesophageal junction adenocarcinoma. Registry status and dates can change. Check ClinicalTrials.gov before citing enrollment claims. Also note ASPEN-06’s estimated completion fields when judging how soon pivotal gastric data could arrive.
CD47-pathway agents have a mixed industry history. Investors should ask how ALX differentiates evorpacept’s safety and combination strategy from earlier class setbacks. Demand trial IDs, not adjectives, when management uses words like “cornerstone” during the Jefferies chat.
How should investors use FDA oncology resources?
When management discusses endpoints, accelerated approval, or companion diagnostics, cross-check claims against FDA oncology approval and guidance materials. A Jefferies chat does not substitute for labeling, CRL letters, or advisory committee transcripts.
- Announcement date: June 1, 2026
- Fireside chat: June 3, 2026, 5:30 PM ET
- Ticker: ALXO
- Lead candidate: evorpacept
- Second candidate: ALX2004 (EGFR ADC, Phase 1)
- Example trial ID: NCT05002127
What remains unproven?
The June 1 release does not disclose new response rates, hazard ratios, or cash runway figures for the Jefferies slot. Do not invent efficacy claims from a calendar invite. Wait for the webcast transcript or a subsequent 8-K if material updates are filed. If management only repeats prior conference talking points, the stock impact should be limited unless financing rumors fill the gap.
For competitive intelligence teams, capture exact quotes on ALX2004 dose cohorts and on any gastric or breast combination strategies for evorpacept. Map each claim back to a trial ID before updating internal oncology pipeline models.
Related NovaPharma coverage
- Legend Biotech In Vivo CAR-T Data
- Fulcrum SCD Strategic Review
- Bladder Cancer Education and Awareness
Frequently Asked Questions
When is ALX Oncology presenting at Jefferies 2026?
ALX said leadership will hold a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on June 3, 2026, at 5:30 PM ET, with a webcast archived for up to 90 days.
What oncology assets does ALX highlight?
ALX describes evorpacept as its lead immuno-oncology candidate in multiple trials and ALX2004 as an EGFR-targeted antibody-drug conjugate in an ongoing Phase 1 dose-escalation study in EGFR-expressing solid tumors.
Does a Jefferies fireside chat change clinical data?
No. A conference fireside chat is an investor communications event. It does not itself create new FDA decisions or replace peer-reviewed or registry trial results.
Primary Sources
ALX Oncology pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…